Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Ohmori

Showing results (421-430 of 437) with videos related to

Pageof 44
Sort By:
European Journal of Epidemiology|June 1, 1997
Effect of maternal lifestyle on cord blood IgE factorT Shirakawa, K Morimoto, S Sasaki, et al.
Cancer Research|February 2, 1999
Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigenT Ise, G Nagatani, T Imamura, et al.
International Journal of Sports Medicine|April 27, 2016
Effects of Cold Stimulation on Mitochondrial Activity and VEGF Expression in vitroT Sugasawa, N Mukai, K Tamura, et al.
Journal of Cardiovascular Pharmacology|January 29, 2002
Neurally mediated syncope and cardiac beta-adrenergic receptor functionS Boh-Oka, H Ohmori, T Kawabe, et al.
Journal of Epidemiology|March 1, 2000
Randomized controlled trial of exercise training for older people (Sendai Silver Center Trial; SSCT): study design and primary outcomeI Tsuji, A Tamagawa, R Nagatomi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 1, 1997
[Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group]H Akaza, N Miyanaga, T Tsukamoto, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 5, 1999
Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuriaN Miyanaga, H Akaza, T Tsukamoto, et al.
Anti-Cancer Drug Design|July 16, 1999
Structural and functional analysis of the control region of the human DNA topoisomerase II alpha gene in drug-resistant cellsH Takano, T Ise, M Nomoto, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 1, 1997
[Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group]H Akaza, N Miyanaga, T Tsukamoto, et al.
Journal of Medical Genetics|April 3, 2004
Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of familial amyloidotic polyneuropathyH Ohmori, Y Ando, Y Makita, et al.
Pageof 44

Showing results (421-430 of 437) with videos related to

Sort By:
Pageof 44
European Journal of Epidemiology|June 1, 1997
Effect of maternal lifestyle on cord blood IgE factorT Shirakawa, K Morimoto, S Sasaki, et al.
Cancer Research|February 2, 1999
Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigenT Ise, G Nagatani, T Imamura, et al.
International Journal of Sports Medicine|April 27, 2016
Effects of Cold Stimulation on Mitochondrial Activity and VEGF Expression in vitroT Sugasawa, N Mukai, K Tamura, et al.
Journal of Cardiovascular Pharmacology|January 29, 2002
Neurally mediated syncope and cardiac beta-adrenergic receptor functionS Boh-Oka, H Ohmori, T Kawabe, et al.
Journal of Epidemiology|March 1, 2000
Randomized controlled trial of exercise training for older people (Sendai Silver Center Trial; SSCT): study design and primary outcomeI Tsuji, A Tamagawa, R Nagatomi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 1, 1997
[Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group]H Akaza, N Miyanaga, T Tsukamoto, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 5, 1999
Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuriaN Miyanaga, H Akaza, T Tsukamoto, et al.
Anti-Cancer Drug Design|July 16, 1999
Structural and functional analysis of the control region of the human DNA topoisomerase II alpha gene in drug-resistant cellsH Takano, T Ise, M Nomoto, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 1, 1997
[Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group]H Akaza, N Miyanaga, T Tsukamoto, et al.
Journal of Medical Genetics|April 3, 2004
Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of familial amyloidotic polyneuropathyH Ohmori, Y Ando, Y Makita, et al.
Pageof 44